624 related articles for article (PubMed ID: 16055573)
1. Quad screen as a predictor of adverse pregnancy outcome.
Dugoff L; Hobbins JC; Malone FD; Vidaver J; Sullivan L; Canick JA; Lambert-Messerlian GM; Porter TF; Luthy DA; Comstock CH; Saade G; Eddleman K; Merkatz IR; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
Obstet Gynecol; 2005 Aug; 106(2):260-7. PubMed ID: 16055573
[TBL] [Abstract][Full Text] [Related]
2. Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome.
Huang T; Hoffman B; Meschino W; Kingdom J; Okun N
Prenat Diagn; 2010 May; 30(5):471-7. PubMed ID: 20440736
[TBL] [Abstract][Full Text] [Related]
3. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome.
Wax JR; Lopes AM; Benn PA; Lerer T; Steinfeld JD; Ingardia CJ
J Matern Fetal Med; 2000; 9(3):161-4. PubMed ID: 10914623
[TBL] [Abstract][Full Text] [Related]
4. Obstetrical complications associated with abnormal maternal serum markers analytes.
Gagnon A; Wilson RD;
J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the thresholds of abnormal second trimester multiple marker screening tests associated with intra-uterine growth restriction.
Odibo AO; Sehdev HM; Stamilio DM; Macones GA
Am J Perinatol; 2006 Aug; 23(6):363-7. PubMed ID: 16841275
[TBL] [Abstract][Full Text] [Related]
6. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns.
Sayin NC; Canda MT; Ahmet N; Arda S; Süt N; Varol FG
Arch Gynecol Obstet; 2008 Jan; 277(1):47-53. PubMed ID: 17653738
[TBL] [Abstract][Full Text] [Related]
7. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies.
Benn PA
Prenat Diagn; 1998 Apr; 18(4):319-24. PubMed ID: 9602476
[TBL] [Abstract][Full Text] [Related]
8. Early detection of preeclampsia using inhibin a and other second-trimester serum markers.
Ree PH; Hahn WB; Chang SW; Jung SH; Kang JH; Cha DH; Kang MS; Huh JY
Fetal Diagn Ther; 2011; 29(4):280-6. PubMed ID: 21252475
[TBL] [Abstract][Full Text] [Related]
9. The ability of the quadruple test to predict adverse perinatal outcomes in a high-risk obstetric population.
Lao MR; Calhoun BC; Bracero LA; Wang Y; Seybold DJ; Broce M; Hatjis CG
J Med Screen; 2009; 16(2):55-9. PubMed ID: 19564516
[TBL] [Abstract][Full Text] [Related]
10. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers.
Wald NJ; Morris JK; Ibison J; Wu T; George LM
Prenat Diagn; 2006 Jun; 26(6):559-64. PubMed ID: 16700087
[TBL] [Abstract][Full Text] [Related]
11. [Pregnancy complications with abnormal results of biochemical screening for Down syndrome in second trimester and normal fetal karyotype].
Dimitrova V; Chernev T; Vragaleva S; Slŭncheva B; Mikhaĭlova E; Kremenski I; Simeonov E
Akush Ginekol (Sofiia); 2002; 41(6):3-12. PubMed ID: 12577497
[TBL] [Abstract][Full Text] [Related]
12. Introduction of a nomogram for predicting adverse pregnancy outcomes based on maternal serum markers in the quad screen test.
An JJ; Ji HY; You JY; Woo SY; Choi SJ; Oh SY; Roh CR; Kim JH
Arch Gynecol Obstet; 2015 Sep; 292(3):589-94. PubMed ID: 25773358
[TBL] [Abstract][Full Text] [Related]
13. Elevated second-trimester maternal serum hCG alone or in combination with elevated alpha-fetoprotein.
Benn PA; Horne D; Briganti S; Rodis JF; Clive JM
Obstet Gynecol; 1996 Feb; 87(2):217-22. PubMed ID: 8559527
[TBL] [Abstract][Full Text] [Related]
14. Maternal serum activin, inhibin, human chorionic gonadotrophin and alpha-fetoprotein as second trimester predictors of pre-eclampsia.
Davidson EJ; Riley SC; Roberts SA; Shearing CH; Groome NP; Martin CW
BJOG; 2003 Jan; 110(1):46-52. PubMed ID: 12504935
[TBL] [Abstract][Full Text] [Related]
15. Triploidy identified through second-trimester serum screening.
Huang T; Alberman E; Wald N; Summers AM
Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
[TBL] [Abstract][Full Text] [Related]
16. Elevated maternal serum alpha-fetoprotein with low unconjugated estriol and the risk for lethal perinatal outcome.
Benn PA; Craffey A; Horne D; Ramsdell L; Rodis JF
J Matern Fetal Med; 2000; 9(3):165-9. PubMed ID: 10914624
[TBL] [Abstract][Full Text] [Related]
17. Second trimester serum markers.
Canick JA; MacRae AR
Semin Perinatol; 2005 Aug; 29(4):203-8. PubMed ID: 16104669
[TBL] [Abstract][Full Text] [Related]
18. Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers.
Dugoff L; Cuckle HS; Hobbins JC; Malone FD; Belfort MA; Nyberg DA; Comstock CH; Saade GR; Eddleman KA; Dar P; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
Am J Obstet Gynecol; 2008 Sep; 199(3):290.e1-6. PubMed ID: 18771987
[TBL] [Abstract][Full Text] [Related]
19. Identification of second trimester screen positive pregnancies at increased risk for congenital heart defects.
Jelliffe-Pawlowski LL; Walton-Haynes L; Currier RJ
Prenat Diagn; 2009 Jun; 29(6):570-7. PubMed ID: 19266536
[TBL] [Abstract][Full Text] [Related]
20. Second trimester total human chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy.
Duric K; Skrablin S; Lesin J; Kalafatic D; Kuvacic I; Suchanek E
Eur J Obstet Gynecol Reprod Biol; 2003 Sep; 110(1):12-5. PubMed ID: 12932863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
